MC-5A for Chemotherapy Induced Peripheral Neuropathy

Completed · Phase 2 · Has a placebo group

Conditions studied: Neuropathy, Paraneoplastic

In brief

Painful chemotherapy induced peripheral neuropathy (CIPN) is a common complication of cancer therapy with few treatment options. CIPN is a complex side effect that varies between individuals and can be difficult to describe, difficult to treat and can significantly effect quality of life for patients. The purpose of this study is to determine if patients with painful CIPN will have a decrease in pain scores after treatment with the MC-5A device.

Key facts

Study ID

NCT01261780

Run by

University of Wisconsin, Madison

People needed

14

Starts

2011-04-01

Expected to finish

2012-09-01

Last updated by the study team

2019-12-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• painful peripheral neuropathy resulting from chemotherapy
• pain must be present for minimum of 6 months
• must be able to read/understand English
• stable analgesics regimens allowed (no change for past 7 days)

You may not qualify if…

• painful peripheral neuropathy that is not the result of chemotherapy
• pregnant women
• patients unable to wean off anti-epileptics
• patients currently receiving chemotherapy known to cause peripheral neuropathy
• patients with pacemakers or implanted defibrillators
• patients with vena cava or aneurysm clips
• patients with a history of epilepsy

Where it is running

• University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.